Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Immunogen Inc (IMGN)

Immunogen Inc (IMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 508,110
  • Shares Outstanding, K 149,885
  • Annual Sales, $ 53,450 K
  • Annual Income, $ -168,840 K
  • 60-Month Beta 2.18
  • Price/Sales 8.83
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.19
  • Number of Estimates 7
  • High Estimate -0.16
  • Low Estimate -0.23
  • Prior Year -0.31
  • Growth Rate Est. (year over year) +38.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.49 +29.32%
on 08/26/19
3.42 -5.85%
on 09/16/19
+0.39 (+13.78%)
since 08/16/19
3-Month
1.81 +77.90%
on 06/27/19
3.42 -5.85%
on 09/16/19
+1.06 (+49.07%)
since 06/17/19
52-Week
1.76 +82.95%
on 05/31/19
9.84 -67.28%
on 10/03/18
-5.49 (-63.03%)
since 09/17/18

Most Recent Stories

More News
ImmunoGen to Present Full Data from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine and Initial Data from Phase 1b FORWARD II Triplet Cohort at ESMO

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that full data and additional exploratory analyses from the...

IMGN : 3.22 (-5.01%)
ImmunoGen (IMGN) Up 18.8% Since Last Earnings Report: Can It Continue?

ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

IMGN : 3.22 (-5.01%)
Jazz Pharma (JAZZ) Q2 Earnings and Sales Beat Estimates

Jazz Pharmaceuticals (JAZZ) reports encouraging second-quarter 2019 earnings and revenues and raises its sales guidance for 2019.

TBPH : 22.64 (-1.48%)
JAZZ : 131.79 (-1.66%)
NBIX : 101.33 (+3.61%)
IMGN : 3.22 (-5.01%)
Advancements for Global Oncology and Cancer Drugs Market Expected to Show High Growth Potential

According to an industry report, the global oncology/cancer drugs market (which was valued at $97,401 Million in 2017) is estimated to reach at $176,509 Million by 2025, registering a CAGR of 7.6% from...

ITCI : 9.16 (-6.34%)
ALLK : 84.07 (-1.44%)
ENDP : 4.10 (-2.38%)
IMGN : 3.22 (-5.01%)
MBRX : 1.28 (+7.56%)
ImmunoGen (IMGN) Stock Down Despite Q2 Earnings & Sales Beat

ImmunoGen (IMGN) reports narrower-than-expected loss in the second quarter and beats revenue estimates. The company provides updated guidance for 2019.

CELG : 98.59 (+0.21%)
IMGN : 3.22 (-5.01%)
ABBV : 71.59 (+1.43%)
RHHBY : 35.1200 (+1.97%)
ImmunoGen (IMGN) Reports Q2 Loss, Tops Revenue Estimates

ImmunoGen (IMGN) delivered earnings and revenue surprises of 9.38% and 50.46%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

IMGN : 3.22 (-5.01%)
ImmunoGen Reports Recent Progress and Second Quarter 2019 Financial Results

--Full Data from the Phase 3 FORWARD I Trial and Initial FORWARD II Triplet Data to be Presented at ESMO

IMGN : 3.22 (-5.01%)
ImmunoGen, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / August 2, 2019 / ImmunoGen, Inc. (NASDAQ: ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on August 2, 2019, 2018 at 8:00 AM Eastern...

IMGN : 3.22 (-5.01%)
Earnings Preview: ImmunoGen (IMGN) Q2 Earnings Expected to Decline

ImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IMGN : 3.22 (-5.01%)
ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2019 Operating Results

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m....

IMGN : 3.22 (-5.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade IMGN with:

Business Summary

ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The company's product candidates are called tumor-activated prodrugs and are based on its proprietary immunoconjugate technology platform. Unlike conventional chemotherapeutic agents, tumor-activated prodrugs are intended...

See More

Key Turning Points

2nd Resistance Point 3.59
1st Resistance Point 3.49
Last Price 3.22
1st Support Level 3.22
2nd Support Level 3.05

See More

52-Week High 9.84
Fibonacci 61.8% 6.75
Fibonacci 50% 5.80
Fibonacci 38.2% 4.85
Last Price 3.22
52-Week Low 1.76

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar